Refine
Year of publication
- 2012 (2) (remove)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Institute
- Medizin (1)
- Rechtswissenschaft (1)
Die rechtsförmige Bewältigung von Leid, Ungerechtigkeit und Unrecht, die durch die kommunistischen Regime der DDR, Osteuropas und der UdSSR verursacht wurden, ist Gegenstand zahlreicher rechts- und geschichtswissenschaftlicher Studien. Untersucht werden die Aufarbeitung des Unrechts durch Strafrecht und die Regelung von Restitution sowie Entschädigung im Fall von Enteignungen. Oft wird – auch infolge der Spezialisierung der jeweiligen Wissenschaftler – das Genre des Länderberichts gewählt. Untersuchungen, die in vergleichender Absicht auch die Aufarbeitung nationalsozialistischen Unrechts einbeziehen, gehen von einer Vergleichbarkeit aus, ohne dass darüber ein neuer Historikerstreit entbrannt wäre. ...
Background: 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC.
Methods: This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial with a sample size of 159 patients from 20 centers in 3 countries. Patients with stage IV colorectal adenocarcinoma limited to liver metastases are included. Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous metastases, eligible patients are randomized 2:1 to receive either L-BLP25 or placebo. Those allocated to L-BLP25 receive a single dose of 300 mg/m2 cyclophosphamide (CP) 3 days before first L-BLP25 dose, then primary treatment with s.c. L-BLP25 930 mug once weekly for 8 weeks, followed by s.c. L-BLP25 930 mug maintenance doses at 6-week (years 1&2) and 12-week (year 3) intervals unless recurrence occurs. In the control arm, CP is replaced by saline solution and L-BLP25 by placebo. Primary endpoint is the comparison of recurrence-free survival (RFS) time between groups. Secondary endpoints are overall survival (OS) time, safety, tolerability, RFS/OS in MUC-1 positive cancers. Exploratory immune response analyses are planned. The primary endpoint will be assessed in Q3 2016. Follow-up will end Q3 2017. Interim analyses are not planned.
Discussion: The design and implementation of such a vaccination study in colorectal cancer is feasible. The study will provide recurrence-free and overall survival rates of groups in an unbiased fashion. Trial Registration EudraCT Number 2011-000218-20